Neuroblastoma pediatric

Laug WE, Siegel SE, Shaw KN, Landing B, Baptista J, Gutenstein M. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978 62 77-83. 

Tuchman M, Ramnaraine ML, Woods WG, Edivit W. Three years of experience with random nrinary homovanillic and vanihyhnandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987 79 ... 

Zambrano E, Reyes-Mugica M. Hormonal activity may predict aggressive behavior in neuroblastoma. Pediatr Dev Pathol 2002 5 190-9. 

Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics. 2013 1312 e336 1. 

Acute lymphoblastic leukemia, Hodgkin s disease, pediatric solid tumors (e.g., Wilms , Ewing s), neuroblastoma... 

Vincristine has been effectively combined with prednisone for remission induction in acute lymphoblastic leukemia in children. It is also active in various hematologicmalignancies such as Hodgkin s and non-Hodgkin s lymphomas, and multiple myeloma, and in several pediatric tumors including rhabdomyosarcoma, neuroblastoma, Ewing s sarcoma, and Wilms tumor. 

Mandel M, Toren A, Rechavi G, Dor J, Ben-Bassat I, Neumann Y. Hormonal treatment in pregnancy a possible risk factor for neuroblastoma. Med Pediatr Oncol 1994 23(2) 133-5. 

DAC (decitabine)+ doxorubicin + cyclophosphamide I Pediatric relapsed/ refractory solid tumors or neuroblastoma NCI... 

Olshan AF, Smith J, Cook MN, Grufferman S, Pollock BH, Stram DO, Seeger RC, Look AT, Cohn SL, Castleberry RP, Bondy ML (1999) Hormone and fertility drug use and the risk of neuroblastoma A report from the Children s Cancer Group and the Pediatric Oncology Group. Am J Epidemiol, 150 930-938. 

Opsoclonus is a disorder of eye movement characterized by multidirectional saccades. Opsoclonus is usually associated with myoclonus, constituting OM, and there are often coexisting signs of cerebellar dysfunction and encephalopathy. The causation of OM is complex, including viral, metabolic, toxic, and structural disorders. Paraneoplastic OM was first described in children. Neuroblastoma is found in 50% of the pediatric OM cases, but on the whole, only 2-3% of all children with neuroblastic tumors have paraneoplastic OM [74, 75]. 

Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma Clinical outcome and antineuronal antibodies-a report from the Children s Cancer Group Study. Med Pediatr Oncol 2001 3 6(6) 612-622. 

Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma A report from the Pediatric Oncology Group. Med Pediatr Oncol 1997 28(4) 284-288. 

Vincristine is part of many chemotherapeutic regimens, based on its lack of myelosuppressive toxicity. It is used, for example, in the treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), lymphomas, neuroblastoma, brain tumors, and Wilms tumor. The generally recommended dose in adults is 1.4 mg/m /week intravenously (5). Some clinicians have recommended an absolute upper limit of 2 mg, but this limitation is still a matter of debate (6). The usual pediatric dosage is 1.5-2 mg/m, but for children weighing 10 kg or less or who have a body surface area less than 1 m, the manufacturers recommend that treatment should be begun at 0.05 mg/kg once a week (5). 

Candito M, Thyss A, Albertini M, Deville A, Politano S, Mariani R, Chambon P. Methylated catecholamine metabolites for diagnosis of neuroblastoma. Med Pediatr Oncol 1992 20 215-20. 

Kelson L, Johnson GA, Smith R. DOPA metabolism in neuroblastoma. Med Pediatr Oncol 1980 8 317-22. 

Massimo L. Neuroblastoma a challenge for pediatric oncology of the third miilenmum. Ann N Y Acad Sci 2002 963 59-62. 

Monsaingeon M, Perel Y> Simonnet G, Corcuff JB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003 162 397-402. 

Young DG. Thoracic neuroblastoma/ganglioneuroma. J Pediatr Surg. 1983 18 37-41. 

Joshi W. Peripheral neuroblastic tumors pathologic classification based on recommendations of international neuroblastoma pathology committee (modification of Shimada classification). Pediatr Dev Pathol. 2000 3 184-199. 

Comito MA, Saveli VH, Cohen MB. CD44 expression in neuroblastoma and related tumors. J Pediatr Hematol Oncol. 1997 19 292-296. 

Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol. 1996 14 25-34. 

Ara T, Fukuzawa M, Kusafuka T, et al. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma association with tumor progression and clinical outcome. J Pediatr Surg. 1998 33 1272-1278. 

George RE, London WB, Gohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma a Pediatric Oncology Group study. / Clin Oncol. 2005 23 6466-6473. 

Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003 41 30-35. 

Tepmongkol S, Heyman S. l MIBG therapy in neuroblastoma mechanisms, rationale, and current status. Med Pediatr Oncol 1999 ... 

Eggert, A., Grotzer, M.A., Zuzak, T.J., Wiewrodt, B.R., Ikegaki, N., andBrodeur, G., Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Medical Pediatric Oncol, 35 (6), 603-607, 2000. 

Shono, K., Tajiri, T, Fujii, Y, Suita, S. (2000) Clinical implication of minimal disease in the bone marrow and peripheral blood in neuroblastoma. J Pediatr Surg, 35, 1415-1420. 

Davidoff AM, Leary MA, Ng CY, Vanin EF. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001 36 30-36. 

---